Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

2 clinical studies listed.

Filters:

Glycogen Storage Disease IXB

Tundra lists 2 Glycogen Storage Disease IXB clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT04454216

GSD VI and GSD IX Natural History

Collection and review of clinical information related to Glycogen Storage Disease Type VI (GSD VI) OR Glycogen Storage Disease Type IX (GSD IX) generated during clinic visits.

Gender: All

Ages: 0 Years - 90 Years

Updated: 2025-05-28

1 state

Glycogen Storage Disease VI
GLYCOGEN STORAGE DISEASE IXa1
GLYCOGEN STORAGE DISEASE IXa2
+4
ENROLLING BY INVITATION

NCT03655223

Early Check: Expanded Screening in Newborns

Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and families who screen positive, and 3) evaluate the Early Check program. The Early Check screening will lead to earlier identification of newborns with rare health conditions in addition to providing important data on the implementation of this model program. Early diagnosis may result in health and development benefits for the newborns. Infants who have newborn screening in North Carolina will be eligible to participate, equating to over 120,000 eligible infants a year. Over 95% of participants are expected to screen negative. Newborns who screen positive and their parents are invited to additional research activities and services. Parents can enroll eligible newborns on the Early Check electronic Research Portal. Screening tests are conducted on residual blood from existing newborn screening dried blood spots. Confirmatory testing is provided free-of-charge for infants who screen positive, and carrier testing is provided to mothers of infants with fragile X. Affected newborns have a physical and developmental evaluation. Their parents have genetic counseling and are invited to participate in surveys and interviews. Ongoing evaluation of the program includes additional parent interviews.

Gender: All

Ages: 1 Day - 31 Days

Updated: 2025-04-04

1 state

Spinal Muscular Atrophy
Fragile X Syndrome
Fragile X - Premutation
+182